Valneva SE (VALN)

Great NEWS21,000,000 ordinary shares bring in 93 Mill. The offering price was set at #$%$4.90 per ordinary share, corresponding to a price of $9.51 per ADS.The 21,000,000 ordinary shares (including in the form of ADSs) issued in the Global Offering will represent a dilution of approximately 17.9% of the share capital of the Company. On an illustrative basis, a shareholder holding 1% of Valneva?s capital before the Global Offering will now hold a stake of 0.82%.The Company believes its cash and cash equivalents, together with the net proceeds of the Global Offering of approximately $93.1 million (#$%$96.0 million), will be sufficient to fund its operations through at least the end of 2024.

Financing through new shares and
a cash burner
The debts are never talked about

Have I predicted the 5 euros
Now privileged get it even below

Dr. Aseem Malhotra. Political Advisor for many countries including USA. Says no to MRNA Jabs
Dr. Aseem Malhotra. (Courtesy of Dr. Aseem Malhotra)
Vaccines & Safety
Doctor Turns Against Messenger RNA COVID-19 Vaccines, Calls for Global Pause
By Zachary Stieber and Jan Jekielek
September 26, 2022 Updated: September 26, 2022

A doctor who promoted COVID-19 vaccines is now calling for health authorities around the world to pause administration of two of the most-widely utilized COVID-19 vaccines, asserting that the benefits from the vaccines may not outweigh the risks.

“There is more than enough evidence—I would say the evidence is overwhelming—to pause the rollout of the vaccine,” Dr. Aseem Malhotra, a British cardiologist and evidence-based medicine expert, told The Epoch Times.

(VAXX) $2.35 ..Potential BEST Vaccine for Covid Prevention with final Phase 3 results in early Q4 and a Alzheimer Vaccine which is Phase 2b ready = this could be the biggest opp of ALL Covid stocks ...GLTA
"The Phase 3 heterologous boost study evaluating UB-612 against COVID-19 in subjects who have received primary immunization from mRNA, adenovirus vector, or inactivated viral vaccines is ongoing. Vaxxinity expects a topline readout in the second half of 2022, and if successful, these data will support global marketing authorization applications."

###

Wow. Very disappointing. JMHO, the price action since the PFE announcement would have told you that there was a lurking omen . I am actually surprised that this was terminated. My guess is the pivot will be to NVAX in Europe and maybe the rest of the world. I’m still trying to figure out what this means for DVAX.

Regarding Lyme, when there is a bottom in this, VALN will be a good buy. Maybe around 15.

GL

Vaccine will multiply and be fruitful and Valn has other products with revenue increasing exponentially!
Income Statement
Currency in EUR. All numbers in thousands
Get access to 40+ years of historical data with Yahoo Finance Plus Essential.
Breakdown
ttm
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Total Revenue
348,085 2021
348,085
110,321
126,196 2020
113,035